Summarized by Masters of Longevity from Longevity Technology.
A news feature on a new UK diagnostic pathway combining a blood biomarker and digital cognitive testing to speed Alzheimer’s diagnosis. Readers will get a clear sense of the article’s focus and why the delivery model matters.
Key Takeaways
- C2N's blood test (PrecivityAD2) is MHRA-registered in the UK and measures amyloid and phosphorylated tau biomarkers in plasma.
- A JAMA study reported the blood test ruled out Alzheimer’s with 92% specificity and confirmed it with 91% sensitivity using a single cutoff.
- A Sweden study found combining digital cognitive testing with the blood biomarker detected biomarker-verified Alzheimer’s with about 90% accuracy.
